Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Medical - Instruments & Supplies
P/S (TTM)
4.5
EV / FCF (TTM)
28.9
Atrion Corporation, along with its affiliated entities, specializes in the development, production, and global distribution of medical devices for fluid management, cardiovascular health, and ophthalmology, reaching markets across the United States, Canada, Europe, and beyond. Its fluid management portfolio includes valves designed to precisely regulate the flow of liquids or gases, vital for various intubation, intravenous, and catheter applications in anesthesia and oncology, and instrumental in promoting infection control in both hospital and home healthcare environments. In the cardiovascular segment, the company offers a Myocardial Protection System that delivers essential fluids and medications, accurately mixes critical drugs, and meticulously controls variables such as temperature and pressure. This division also provides vacuum relief valves for cardiac surgeries, silicone vessel loops used for retracting and occluding blood vessels, and inflation devices crucial for balloon catheter expansion, stent placement, and fluid delivery, along with other products for heart bypass procedures. For ophthalmology, Atrion supplies specialized medical apparatus for sterilizing contact lenses and a range of balloon catheters employed to treat nasolacrimal duct obstructions in pediatric and adult patients. Beyond these core areas, the corporation also manufactures instruments and corresponding single-use items for assessing the activated clotting time of blood, and secure containment solutions for needles and scalpel blades. Furthermore, Atrion fabricates inflation mechanisms and valves for maritime and aerospace safety equipment, essential components for inflatable survival gear and structures, and both unidirectional and bidirectional pressure relief valves. These valves are crucial for safeguarding delicate electronics and various other goods during transit, serving both medical and non-medical contexts. Atrion distributes its comprehensive suite of products to a diverse client base, including medical practitioners, hospitals, clinics, other care facilities, and fellow equipment manufacturers. This distribution is managed through a multi-channel approach, utilizing a dedicated direct sales team, independent representatives, and a broad network of distributors. Established in 1944, Atrion Corporation maintains its primary operational base in Allen, Texas.
www.atrioncorp.comNo one on the platform currently holds ATRI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 29,709 | $13.4M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2024-06-14 | $2.2000 | 2024-06-28 |
| 2024-03-14 | $2.2000 | 2024-03-29 |
| 2023-11-30 | $2.2000 | 2023-12-15 |
No one on the platform has traded ATRI yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ATRIAtrion Corporation | $459.92 | +0.06% | $809M | — |
| AORTArtivion, Inc. | $24.97 | -0.44% | $1.2B | — |
| ASLNASLAN Pharmaceuticals Limited | $0.60 | -14.27% | $777M | — |
| CDMOAvid Bioservices, Inc. | $12.49 | +0.00% | $799M | — |
| CMRXChimerix, Inc. | $8.54 | +0.00% | $801M | — |
| CSIICardiovascular Systems, Inc. | $20.00 | +0.15% | $844M | — |
| HARPHarpoon Therapeutics, Inc. | $23.01 | +0.09% | $865M | — |
Source: Financial Modeling Prep · peers by sector/industry
$ATRI / $NDSN - Shareholder Vote $NDSN MergerBrief.com
View on StockTwits ↗$ATRI Atrion Reports Second Quarter 2024 Results https://www.stocktitan.net/news/ATRI/atrion-reports-second-quarter-2024-ns673xzn6zx2.html
View on StockTwits ↗$ATRI Atrion Corporation (NASDAQ:ATRI): A Diversified Medical Device Powerhouse Delivering Consistent Growth http://beyondspx.com/2024/07/30/atrion-corporation-nasdaqatri-a-diversified-medical-device-powerhouse-delivering-consistent-growth/
View on StockTwits ↗Signal alert: $ATRI - GoldenStar https://stockinvest.us/l/y7ujOWBDqT
View on StockTwits ↗Signal alert: $ATRI - GoldenStar https://stockinvest.us/l/zilCdT9nhD
View on StockTwits ↗From 6/14/2024, looking back across 21 Month-Ends for ATRI, Percentage Change of Average Monthly Price had More Negatives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $ATRI #ATRI #ATRIStock #TickerDD #ATRIPrice https://www.youtube.com/watch?v=c3wZrVmiAuI
View on StockTwits ↗$ATRI our attorneys are investigating the fairness of the proposed sale of Atrion to Nordson Corporation for $460.00 per share in cash; the proposed sales price is below Atrion’s closing price of $462.93 per share on the day before the deal was announced, and thus represents a negative premium; read more at: https://wohlfruchter.com/cases/atrion-corporation/
View on StockTwits ↗$ATRI https://www.intratio.com/stock-forecast/ATRI Our engine reaches the conclusion that the price action of this stock will decrease in the near future and the stock price is in line with the long-term fundamentals of the company
View on StockTwits ↗$ATRI $MDWD $OBIO $BDX another huge move in medtech today https://www.reuters.com/business/healthcare-pharmaceuticals/edwards-lifesciences-sell-critical-care-products-unit-becton-dickinson-42-bln-2024-06-03/
View on StockTwits ↗$ATRI $OBIO $mdwd - some medtech movement today https://www.massdevice.com/nordson-acquire-atrion-800m/
View on StockTwits ↗$ATRI: ATRION to be acquired by Nordson $NDSN for $460.00/share in cash https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240528070900ATRI&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
View on StockTwits ↗$ATRI Atrion Corporation Enters Into Merger Agreement with Nordson Corporation https://www.stocktitan.net/news/ATRI/atrion-corporation-enters-into-merger-agreement-with-nordson-69zlsrkfxdoy.html
View on StockTwits ↗$ATRI $NDSN Nordson to acquire Atrion for $460.00 per share in cash Nordson (NDSN) announced that it has entered into a definitive agreement to acquire Atrion Corporation (ATRI) for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Headquartered in Allen, Texas, Atrion is a manufacturer of proprietary medical products, generating approximately $169 million in annual revenue in 2023. The $460.00 per share in cash price for Atrion represents a total transaction enterprise value of approximately $800M. The transaction is expected to close prior to Nordson's fiscal year-end 2024, pending applicable regulatory and stockholder approvals and will be funded through a combination of cash on hand and newly issued financial debt.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.